SELLAS Life Sciences
NASDAQ · SLS·New York, NY·Small-cap·Phase 3
Late-stage clinical biopharma developing novel cancer therapeutics. Lead asset galinpepimut-S (GPS) is a WT1-directed cancer immunotherapy in Phase 3 REGAL for AML maintenance (interim analysis cleared January 2025). SLS009 (tambiciclib) is a selective CDK9 inhibitor with Phase 2 activity in r/r AML.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| SELLAS Life Sciences Corporate Presentation — February 2026 | Corporate overview | February 3, 2026 | 34 |